| Literature DB >> 11173545 |
S Kubo1, S Nishiguchi, K Hirohashi, H Tanaka, T Tsukamoto, T Shuto, S Takemura, T Yamamoto, T Ikebe, K Wakasa, S Shiomi, H Kinoshita.
Abstract
Interferon (IFN) therapy decreases the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV). One hundred and fifty-nine consecutive patients who underwent liver resection for HCV-related HCC were studied. In 17 (group 1) of the 159 patients, HCC was detected during or after IFN therapy. The incidences of recurrence after surgery in the group 1 patients and the other 142 patients (group 2) were compared. Eight patients had a complete response to IFN, 4 had a partial response, and 5 had no response. The proportion of patients without HCV viremia was significantly higher in the group 1 patients (P < 0.0001). The tumor-free survival rate was significantly higher in the group 1 patients (P = 0.0010). By multivariate analysis of various risk factors for recurrence, no previous IFN was a significant independent risk factor for recurrence (risk ratio = 6.336; 95%CI, 1.512 - 26.50). The patients with HCC who underwent IFN therapy previously are good candidates for liver resection because recurrence after the operation was rarely observed.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11173545 PMCID： PMC5926579 DOI： 10.1111/j.1349-7006.2001.tb01048.x
Source DB: PubMed Journal: Jpn J Cancer Res ISSN： 0910-5050